Apricus Biosciences Inc (APRI) Releases Earnings Results, Misses Estimates By $0.21 EPS
Apricus Biosciences Inc (NASDAQ:APRI) posted its quarterly earnings data on Thursday. The company reported $1.04 earnings per share for the quarter, missing the consensus estimate of $1.25 by $0.21. During the same period last year, the business earned ($0.50) earnings per share.
Apricus Biosciences (NASDAQ:APRI) traded down 11.02% during trading on Friday, hitting $1.13. The company had a trading volume of 456,708 shares. The stock’s market capitalization is $8.75 million. The stock has a 50-day moving average of $1.62 and a 200-day moving average of $1.94. Apricus Biosciences has a one year low of $0.95 and a one year high of $5.95.
Several equities analysts recently weighed in on APRI shares. Zacks Investment Research cut Apricus Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, January 31st. Rodman & Renshaw started coverage on Apricus Biosciences in a research report on Wednesday, April 26th. They set a “buy” rating for the company.
ILLEGAL ACTIVITY WARNING: This news story was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.americanbankingnews.com/2017/05/12/apricus-biosciences-inc-apri-releases-earnings-results-misses-estimates-by-0-21-eps.html.
Apricus Biosciences Company Profile
Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.
Receive News & Ratings for Apricus Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.